Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: positive revenue growth and pipeline developments are countered by declining margins, increased expenses, and a net loss. The raised revenue guidance is a positive sign, but the lack of clarity on reimbursement pathways and flat SCC volumes temper enthusiasm. The Q&A reveals some analyst concerns, particularly regarding reimbursement and FDA approval impacts. The absence of a market cap limits prediction accuracy, but the overall sentiment leans towards neutral, given the balancing of positive growth prospects against financial pressures and uncertainties.
Key Financial Performance
Revenue Revenue reached $83 million, representing a significant increase compared to the third quarter of 2024. This growth was driven by a 36% increase in total test report volume, highlighting the success of strategic initiatives and operational strength.
DecisionDx-Melanoma Test Reports 10,459 reports were delivered in the quarter, representing a 12% year-over-year increase. This milestone marks the first time the company surpassed 10,000 reports in a single quarter, driven by strong adoption and clinical utility.
DecisionDx-SCC Test Reports 4,186 test reports were delivered in the third quarter of 2025. This volume was achieved without proactive marketing, underscoring the clinical value and growing evidence supporting the test.
TissueCypher Test Reports 10,609 test reports were delivered in the third quarter, representing a 75% year-over-year growth. This milestone indicates increasing recognition of the test's value by clinicians.
Gross Margin Gross margin during the third quarter of 2025 was 74.7%, compared to 79.2% in the third quarter of 2024. The decline was attributed to higher personnel costs, lab supplies, and lab service expenses due to increased test report volumes.
Operating Expenses Total operating expenses, including cost of sales, were $89.8 million in Q3 2025 compared to $80.7 million in Q3 2024. The increase was driven by higher personnel costs, travel expenses, marketing expenses, and IT-related costs.
Net Loss Net loss for Q3 2025 was $0.5 million compared to net income of $2.3 million in Q3 2024. This shift was influenced by increased operating expenses and investments in growth initiatives.
Adjusted EBITDA Adjusted EBITDA for Q3 2025 was $9.2 million compared to $21.6 million in Q3 2024. The decline reflects higher operating expenses despite strong revenue growth.
Net Cash Provided by Operating Activities Net cash provided by operating activities was $22.6 million for Q3 2025, reflecting strong operational performance and cash flow management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of AdvanceAD-Tx: Castle Biosciences launched AdvanceAD-Tx, a test designed to guide systemic treatment selection for patients with moderate to severe atopic dermatitis. The test evaluates the expression of 487 genes across 12 immune inflammatory and skin-related pathways. It aims to improve patient outcomes by enabling precision medicine in atopic dermatitis management.
Market size for AdvanceAD-Tx: The target patient population for AdvanceAD-Tx in the U.S. is estimated at 13.2 million individuals aged 12 and older with moderate to severe atopic dermatitis, representing a $33 billion total addressable market opportunity.
Revenue growth: Revenue for Q3 2025 reached $83 million, with total test report volume of 26,841, representing a 36% growth compared to Q3 2024. Full-year revenue guidance was raised to $327 million to $335 million.
Test performance: DecisionDx-Melanoma delivered 10,459 reports in Q3 2025, a 12% year-over-year increase. TissueCypher achieved 10,609 test reports, a 75% year-over-year growth.
Reimbursement strategy for AdvanceAD-Tx: Castle Biosciences is pursuing multiple pathways to accelerate patient access to AdvanceAD-Tx, with revenue contribution expected to be immaterial in 2026 as reimbursement is built from ground zero.
Focus on DecisionDx-Melanoma: The company plans to focus its commercial team on DecisionDx-Melanoma while introducing AdvanceAD-Tx in a phased manner throughout 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Reimbursement Challenges: The company is building reimbursement for the new AdvanceAD-Tx test from ground zero, which is expected to result in immaterial revenue contribution in 2026. This creates uncertainty in revenue generation and financial performance.
High Operating Expenses: Operating expenses, including cost of sales, increased to $89.8 million in Q3 2025 from $80.7 million in Q3 2024. This rise is attributed to higher personnel costs, travel, marketing, and lab-related expenses, which could pressure profitability.
Declining Gross Margin: Gross margin decreased to 74.7% in Q3 2025 from 79.2% in Q3 2024, indicating potential challenges in maintaining cost efficiency as the business scales.
Regulatory and Coverage Risks: The company submitted LCD reconsideration requests for its DecisionDx-SCC test, but there is no specified timeline or guarantee of coverage approval, which could impact the test's market adoption and revenue.
Dependence on Key Products: The company’s revenue heavily relies on a few core tests like DecisionDx-Melanoma and DecisionDx-SCC. Any market or operational challenges affecting these products could significantly impact financial performance.
Market Adoption of New Products: The success of the newly launched AdvanceAD-Tx test depends on market adoption and physician acceptance, which, despite positive initial feedback, remains uncertain.
Economic and Inflationary Pressures: Higher personnel costs and inflationary wage adjustments are contributing to increased expenses, which could impact profitability if not offset by revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Castle Biosciences raised its total revenue guidance for 2025 to a range of $327 million to $335 million, up from the previously provided range of $310 million to $320 million.
Launch of AdvanceAD-Tx: The company announced the launch of AdvanceAD-Tx, a test designed to guide systemic treatment selection for patients with moderate to severe atopic dermatitis. The test will be clinically launched on a limited access model in November 2025, with phased expansion throughout 2026. Revenue contribution from this test is expected to be immaterial in 2026 as reimbursement is built from ground zero.
Market Opportunity for AdvanceAD-Tx: The target patient population for AdvanceAD-Tx represents an approximately $33 billion total addressable market opportunity in the U.S. alone, based on a 1-year prevalence of 13.2 million individuals aged 12 and older with moderate to severe atopic dermatitis.
DecisionDx-Melanoma Test: The company expects high single-digit volume growth for DecisionDx-Melanoma for the full year 2025 compared to 2024.
Reimbursement Strategy for AdvanceAD-Tx: Castle Biosciences is pursuing multiple pathways to accelerate patient access to AdvanceAD-Tx, recognizing the need to build a new market and evaluate all available options.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you provide more color on who would be addressable from the 13.2 million patients? And if it is all of them, how many of these patients are Medicare age?
A:The 13.2 million patients represent the U.S. target market for moderate to severe atopic dermatitis. Approximately 10%-20% of these patients are estimated to be of Medicare age.
Q:Could you tell us a little bit more about the multiple reimbursement pathways?
A:The test aims to result in more medically appropriate recommendations for Medicare patients. However, the company refrained from providing further details on commercial payment or other payer opportunities at this time.
Q:Can you share updates on the reconsideration request for SCC and its timing?
A:The reconsideration request was deemed valid by Medicare contractors Novitas and MolDx due to new clinical data. However, there is no specific timeline for the process as it depends on the contractors' working pace.
Q:Why did SCC volumes seem flattish to down quarter-over-quarter, and what caused the sequential decline in gross margin?
A:SCC volumes remained stable, which the company views as a positive sign of clinical utility. The gross margin decline was partly due to modest revenue from commercial claims on SCC, which was not material.
Q:What drove the 5% sequential growth in DecisionDx-Melanoma volumes in Q3, and what is the outlook for Q4?
A:The growth was attributed to increased focus by the dermatology sales force on melanoma tests starting in July. For Q4, the company expects volumes to be flat or slightly down due to seasonality and holidays.
Q:What is driving growth in DecisionDx-Melanoma, and is it from new or existing clinicians?
A:Growth is driven by both new ordering clinicians and increased utilization among existing ones. The company continues to see room for expansion in both areas.
Q:What does the updated guidance imply for DecisionDx-SCC revenue and its contribution in the quarter?
A:DecisionDx-SCC contributed mid-single-digit millions in revenue, which was modest. The company does not expect continued SCC revenue and assumes it will fall off to be conservative.
Q:What is the market penetration and outlook for TissueCypher?
A:TissueCypher is in the early growth phase with significant room for expansion. The company estimates 420,000 patients diagnosed annually with Barrett's esophagus could benefit from the test. No immediate guideline changes are expected to impact penetration.
Q:What is the status and potential impact of FDA approval for DecisionDx-Melanoma?
A:The company is preparing an FDA application following breakthrough designation. FDA approval is not expected to change the Medicare rate but may help with compliance to state biomarker laws and commercial payer reimbursement in the long term.
Q:What is the current sales force size for TissueCypher, and did the Prebuys acquisition impact Q3 results?
A:The company did not disclose the exact sales force size but stated it remains under 100. The Prebuys acquisition had no impact on Q3 results.
Q:Have there been any engagements with biopharma companies regarding Advance-Tx and JAK inhibitors?
A:The company did not provide specific details but acknowledged potential synergies in identifying patients who may respond better to certain therapies.
Q:Will the company continue accepting orders for SCC despite reimbursement challenges?
A:Yes, the company plans to continue offering the SCC test to advance patient care, even amid reimbursement uncertainties.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or sufficient details on multiple reimbursement pathways, the potential impact of FDA approval on Medicare rates, and engagements with biopharma companies regarding Advance-Tx.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AdvanceAD Tx
JAK inhibitor
Melanoma DecisionDx
NCCN risk
Th pathway
access
age dermatitis
care risk
class therapy
commitment care
decision making
disease
escalation
finding
grade dysplasia
individual
inhibitor responder
lab supply
launch AdvanceAD
market opportunity
model
pathway Th
patient JAK
patient dermatitis
patient risk
prescription
request
responder profile
risk progression
scale
staging
strategy overtreatment
symptom
therapeutic
utility DecisionDx
CSTL Transcript
Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance with a 25% revenue increase, improved gross margin, and a shift from net loss to net income. Although operating expenses rose, they were due to strategic investments. The guidance for 2026 indicates continued growth, and cash flow improvements further reinforce a positive outlook. Despite inherent risks in forward-looking statements, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call highlights increased operating expenses and a net loss for 2025, contrasting with a previous net income. Adjusted EBITDA has significantly decreased, and there is uncertainty around FDA approval and NCCN guideline inclusion for key products. Despite strong market opportunities and revenue guidance, these financial concerns and vague management responses suggest a negative market reaction.
Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript
Unknown11-3
The earnings call presents mixed signals: positive revenue growth and pipeline developments are countered by declining margins, increased expenses, and a net loss. The raised revenue guidance is a positive sign, but the lack of clarity on reimbursement pathways and flat SCC volumes temper enthusiasm. The Q&A reveals some analyst concerns, particularly regarding reimbursement and FDA approval impacts. The absence of a market cap limits prediction accuracy, but the overall sentiment leans towards neutral, given the balancing of positive growth prospects against financial pressures and uncertainties.
Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript
Positive8-4
The earnings call summary and Q&A indicate positive sentiment, driven by raised revenue guidance, strong growth in TissueCypher and DecisionDx-Melanoma tests, and optimistic future cash flow expectations. Despite some uncertainties in FDA submission timelines and reimbursement pathways, the overall outlook is upbeat. The company's strategic initiatives and growth potential in the GI space further bolster confidence. The market is likely to react positively, with stock price expected to rise by 2% to 8% over the next two weeks.
CSTL Slides
CSTL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
